MA46356B1 - Inhibiteurs de bêta-lactamases - Google Patents

Inhibiteurs de bêta-lactamases

Info

Publication number
MA46356B1
MA46356B1 MA46356A MA46356A MA46356B1 MA 46356 B1 MA46356 B1 MA 46356B1 MA 46356 A MA46356 A MA 46356A MA 46356 A MA46356 A MA 46356A MA 46356 B1 MA46356 B1 MA 46356B1
Authority
MA
Morocco
Prior art keywords
beta
lactamase inhibitors
compounds
relates
gram
Prior art date
Application number
MA46356A
Other languages
English (en)
Inventor
Robert Lowell Simmons
Anthony Casarez
Xiaodong Lin
Folkert Reck
Qingming Zhu
Markus Furegati
Guido Koch
Flavio Ossola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46356B1 publication Critical patent/MA46356B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne de manière générale des composés de formule (a), tels que décrits ici, qui agissent en tant qu'inhibiteurs de bêta-lactamase, et des sels, des formes cristallines et des formulations de ceux-ci. Dans certains aspects, l'invention concerne des procédés d'utilisation de tels composés en combinaison avec un antibiotique bêta-lactame pour traiter des infections provoquées par des bactéries à gram négatif, y compris des souches résistantes aux médicaments.
MA46356A 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases MA46356B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401022P 2016-09-28 2016-09-28
PCT/IB2017/055973 WO2018060926A1 (fr) 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases

Publications (1)

Publication Number Publication Date
MA46356B1 true MA46356B1 (fr) 2020-08-31

Family

ID=60191429

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050427A MA50427A (fr) 2016-09-28 2017-09-28 Combinaison pharmaceutique entre un inhibiteur tricyclique de bêta-lactamase et des antibiotiques spécifiques de bêta-lactamase
MA46356A MA46356B1 (fr) 2016-09-28 2017-09-28 Inhibiteurs de bêta-lactamases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050427A MA50427A (fr) 2016-09-28 2017-09-28 Combinaison pharmaceutique entre un inhibiteur tricyclique de bêta-lactamase et des antibiotiques spécifiques de bêta-lactamase

Country Status (42)

Country Link
US (2) US10597396B2 (fr)
EP (2) EP3519419B1 (fr)
JP (1) JP7094275B2 (fr)
KR (1) KR20190058492A (fr)
CN (1) CN109843894B (fr)
AR (1) AR109737A1 (fr)
AU (1) AU2017335405B2 (fr)
BR (1) BR112019002195A2 (fr)
CA (1) CA3030373A1 (fr)
CL (1) CL2019000232A1 (fr)
CO (1) CO2019001995A2 (fr)
CR (1) CR20190104A (fr)
CU (1) CU24562B1 (fr)
CY (1) CY1123062T1 (fr)
DK (1) DK3519419T3 (fr)
EA (1) EA036675B1 (fr)
EC (1) ECSP19016602A (fr)
ES (2) ES2902579T3 (fr)
HR (1) HRP20200986T1 (fr)
HU (1) HUE049788T2 (fr)
IL (1) IL265626B (fr)
JO (1) JOP20190061A1 (fr)
LT (1) LT3519419T (fr)
MA (2) MA50427A (fr)
MD (1) MD3519419T2 (fr)
ME (1) ME03735B (fr)
MX (1) MX380076B (fr)
MY (1) MY189632A (fr)
PE (1) PE20190459A1 (fr)
PH (1) PH12019500331A1 (fr)
PL (1) PL3519419T3 (fr)
PT (1) PT3519419T (fr)
RS (1) RS60483B1 (fr)
SG (1) SG11201900394SA (fr)
SI (1) SI3519419T1 (fr)
SM (1) SMT202000343T1 (fr)
TN (1) TN2019000020A1 (fr)
TW (1) TWI746652B (fr)
UA (1) UA123833C2 (fr)
UY (1) UY37424A (fr)
WO (1) WO2018060926A1 (fr)
ZA (1) ZA201900137B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
US11897844B2 (en) 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
CN115368261A (zh) * 2022-07-29 2022-11-22 武汉理工大学 N-烯丙基-n-苄基-2-(苄基氨基)乙酰胺的合成方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
CA2143519A1 (fr) * 1994-03-11 1995-09-12 F. Hoffmann-La Roche Ag Beta-lactames
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
CA2263129C (fr) 1996-08-16 2007-01-09 Schering Corporation Antigenes de surface de cellules mammaliennes et reactifs qui y sont lies
CA2308114A1 (fr) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
DK1196186T3 (da) 1999-07-12 2008-03-03 Genentech Inc Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (fr) 2004-06-04 2007-03-28 Duke University Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
CA2602777C (fr) 2005-03-25 2018-12-11 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
EP1981969A4 (fr) 2006-01-19 2009-06-03 Genzyme Corp Anticorps anti-gitr destines au traitement du cancer
WO2008039420A2 (fr) 2006-09-27 2008-04-03 Merck & Co., Inc. Nouveaux inhibiteurs de bêta-lactamase
EP3222634A1 (fr) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
SI2666774T1 (sl) * 2008-01-18 2015-04-30 Merck Sharp & Dohme Corp. Inhibitorji beta- laktamaze
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2010126820A2 (fr) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Préparation d'esters alkyliques d'acides oxo-azacycloalkylcarboxyliques n-protégés
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
MX340533B (es) * 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9025112B2 (en) 2012-02-02 2015-05-05 Apple Inc. Display with color mixing prevention structures
EP2814483A2 (fr) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Méthodes de traitement d'infections bactériennes
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014033560A1 (fr) 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes
WO2014141132A1 (fr) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase
JP6411482B2 (ja) * 2013-10-11 2018-10-24 ウォックハート リミテッド 窒素含有化合物およびその使用
WO2016116788A1 (fr) * 2015-01-24 2016-07-28 Wockhardt Limited Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
KR20170132316A (ko) * 2015-04-03 2017-12-01 무타빌리스 헤테로고리 화합물 및 박테리아 감염의 예방 또는 치료에서 그들의 용도
EP3075381A1 (fr) * 2015-04-03 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز

Also Published As

Publication number Publication date
KR20190058492A (ko) 2019-05-29
BR112019002195A2 (pt) 2019-05-14
CR20190104A (es) 2019-05-02
ME03735B (fr) 2021-01-20
UA123833C2 (uk) 2021-06-09
PE20190459A1 (es) 2019-04-01
MX380076B (es) 2025-03-11
US20180086762A1 (en) 2018-03-29
EP3698796B1 (fr) 2021-10-27
MA50427A (fr) 2021-05-12
AR109737A1 (es) 2019-01-16
TN2019000020A1 (en) 2020-07-15
LT3519419T (lt) 2020-09-10
HUE049788T2 (hu) 2020-10-28
MX2019003640A (es) 2019-08-12
CU24562B1 (es) 2022-01-13
CU20190016A7 (es) 2019-10-04
ECSP19016602A (es) 2019-03-29
US10597396B2 (en) 2020-03-24
EA036675B1 (ru) 2020-12-07
EP3519419A1 (fr) 2019-08-07
PL3519419T3 (pl) 2020-11-02
CO2019001995A2 (es) 2019-03-08
AU2017335405A1 (en) 2019-01-31
PH12019500331A1 (en) 2019-08-05
ES2902579T3 (es) 2022-03-29
CN109843894B (zh) 2022-02-08
CA3030373A1 (fr) 2018-04-05
SG11201900394SA (en) 2019-04-29
IL265626B (en) 2021-08-31
WO2018060926A1 (fr) 2018-04-05
JP7094275B2 (ja) 2022-07-01
ES2801874T3 (es) 2021-01-14
US20190177324A1 (en) 2019-06-13
US10065957B2 (en) 2018-09-04
HRP20200986T1 (hr) 2020-10-16
DK3519419T3 (da) 2020-06-29
MD3519419T2 (ro) 2020-08-31
SMT202000343T1 (it) 2020-07-08
CY1123062T1 (el) 2021-10-29
TW201817730A (zh) 2018-05-16
IL265626A (en) 2019-05-30
EP3698796A1 (fr) 2020-08-26
JOP20190061A1 (ar) 2019-03-26
PT3519419T (pt) 2020-06-26
TWI746652B (zh) 2021-11-21
ZA201900137B (en) 2019-09-25
CL2019000232A1 (es) 2019-05-10
MY189632A (en) 2022-02-22
UY37424A (es) 2018-04-30
RS60483B1 (sr) 2020-08-31
EP3519419B1 (fr) 2020-05-27
SI3519419T1 (sl) 2020-09-30
CN109843894A (zh) 2019-06-04
EA201990819A1 (ru) 2019-08-30
JP2019529469A (ja) 2019-10-17
AU2017335405B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MX385507B (es) Compuestos inhibidores de beta-lactamasa
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA46356B1 (fr) Inhibiteurs de bêta-lactamases
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA38922A3 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
MA42244A (fr) Dérivés de 3-tétrazolyl-benzène-1,2-disulfonamide en tant qu'inhibiteurs de métallo-bêta-lactamase
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA40254B1 (fr) Polymorphes du selinexor
MA54386B1 (fr) Modulateurs de trex1
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
BR112017023359A2 (pt) ?compostos, composições farmacêuticas e kits?
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines